Bioventus Inc.
BVS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $573 | $512 | $512 | $431 |
| % Growth | 11.9% | 0% | 18.8% | – |
| Cost of Goods Sold | $185 | $184 | $181 | $128 |
| Gross Profit | $388 | $328 | $331 | $303 |
| % Margin | 67.7% | 64.1% | 64.6% | 70.3% |
| R&D Expenses | $14 | $13 | $24 | $19 |
| G&A Expenses | $323 | $300 | $327 | $0 |
| SG&A Expenses | $327 | $304 | $332 | $254 |
| Sales & Mktg Exp. | $4 | $4 | $5 | $0 |
| Other Operating Expenses | $59 | $93 | $142 | $17 |
| Operating Expenses | $400 | $410 | $498 | $291 |
| Operating Income | -$12 | -$82 | -$167 | $12 |
| % Margin | -2.1% | -16% | -32.7% | 2.8% |
| Other Income/Exp. Net | -$37 | -$39 | -$22 | -$3 |
| Pre-Tax Income | -$49 | -$121 | -$189 | $9 |
| Tax Expense | -$5 | $0 | -$44 | -$2 |
| Net Income | -$34 | -$156 | -$159 | $19 |
| % Margin | -5.9% | -30.5% | -31% | 4.5% |
| EPS | -0.52 | -2.49 | -2.59 | -0.15 |
| % Growth | 79.1% | 3.9% | -1,626.7% | – |
| EPS Diluted | -0.52 | -2.49 | -2.59 | -0.15 |
| Weighted Avg Shares Out | 65 | 63 | 61 | 45 |
| Weighted Avg Shares Out Dil | 65 | 63 | 61 | 45 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $39 | $41 | $12 | $1 |
| Depreciation & Amortization | $50 | $57 | $55 | $35 |
| EBITDA | $39 | -$23 | -$122 | $45 |
| % Margin | 6.8% | -4.5% | -23.7% | 10.6% |